Bio-Techne's Q1 FY2026 results were impacted by order timing from its largest cell therapy customers who received FDA fast-track designations, causing a 1% organic revenue decline. Management expects this headwind to worsen in Q2 before moderating, but maintained its full-year low-single-digit growth guidance, citing improving biotech funding and stabilization in academic markets. Q1 organic revenue declined 1% year-over-year to $286.6M, missing expectations due to a 200 bps headwind from two key cell therapy customers that received FDA fast-track designations.
Buzzberg 분석Q2 growth expected flat despite 400bps cell therapy headwindBio-Techne's Q1 FY2026 results were impacted by order timing from its largest cell therapy customers who received FDA fast-track designations, causing a 1% organic revenue decline. Management expects this headwind to worsen in Q2 before moderating, but maintained its full-year low-single-digit growth guidance, citing improving biotech funding and stabilization in academic markets. Q1 organic revenue declined 1% year-over-year to $286.6M, missing expectations due to a 200 bps headwind from two key cell therapy customers that received FDA fast-track designations.전체 분석 보기분석 접기
Bio-Techne's Q1 FY2026 results were impacted by order timing from its largest cell therapy customers who received FDA fast-track designations, causing a 1% organic revenue decline. Management expects this headwind to worsen in Q2 before moderating, but maintained its full-year low-single-digit growth guidance, citing improving biotech funding and stabilization in academic markets. Q1 organic revenue declined 1% year-over-year to $286.6M, missing expectations due to a 200 bps headwind from two key cell therapy customers that received FDA fast-track designations.
Adjusted operating margin expanded 90 bps to 29.9%, exceeding expectations due to cost management, though the GMP protein business experienced a temporary demand air pocket.
The cell therapy headwind is expected to intensify in Q2 (400 bps), with management guiding Q2 organic growth to be roughly flat (consistent with Q1).
Management maintains its full-year low-single-digit organic growth guidance, citing improving biotech funding (October was the strongest month), signs of stabilization in U.S. academia, and strong growth in China (second consecutive quarter).
Cell therapy headwind intensifies in Q2, fades in H2
Q1 organic revenue declined 1% year-over-year to $286.6M, missing expectations due to a 200 bps headwind from two key cell therapy customers that received FDA fast-track designations.
03
Macro
Biotech funding shows early stabilization signs
Adjusted operating margin expanded 90 bps to 29.9%, exceeding expectations due to cost management, though the GMP protein business experienced a temporary demand air pocket.
04
Demand
Large pharma demand remains strong, growing low double digits
Management balanced acknowledging headwinds (cell therapy timing, biotech funding) with signs of stabilization and maintained low single-digit growth outlook.
수요
수요
수주 및 전환
Large pharma demand remains strong, growing low double digits. Management balanced acknowledging headwinds (cell therapy timing, biotech funding) with signs of stabilization and maintained low single-digit growth outlook.
톤 · Measured
Management balanced acknowledging headwinds (cell therapy timing, biotech funding) with signs of stabilization and maintained low single-digit growth outlook.
공급망 알파
A1
Bio-Techne's top two cell therapy customers, which received FDA fast-track designation, have shifted from ordering reagents for clinical trials to preparing for commercial launch, creating a significant near-term demand air pocket.
“These customers have ordered enough to finalize their clinical trials... the materials for their phase three, for what they have to do, would already, in our assumptions, have ordered last year. And the materials that you would need for co…”
The recent wave of U.S. biopharma manufacturing investment, driven by onshoring initiatives, is expected to be a growth catalyst for Bio-Techne's Maurice biologics QA/QC platform as new sites adopt similar instrumentation.
“We see recent U.S. manufacturing investment announcements by several large pharmaceutical companies as a potential catalyst for accelerating growth in this business.”
The expanded agreement with Oxford Nanopore builds on a successful product launch, indicating a deepening partnership that should benefit both companies' sales of sequencing kits and platforms.
“We also announced an expanded agreement with Oxford Nanopore Technologies, building on last year's successful launch of the Amplidex Nanopore Carrier Plus kit.”
… compared to the standard treatment. We also launched the Amplidex PML-RAGA kit, a multiplex QPCR assay designed to detect all three major fusion variants associated with APL, an aggressive form of leukemia. This assay runs on widely installed QPCR platforms and delivers results in approximately four hours. This launch problems our hematology menu alongside the Quantidex PCR-ABLE kit and positions us for continued menu expansion. We also announced an expanded agreement with Oxford Nanopore Technologies, building on last year's successful launch of the Amplidex Nanopore Carrier Plus kit. This comprehensive carrier scaling panel targets 11 hard-to-sequence genes in a single workflow, offering laboratories a streamlined and efficient solution for genetic testing. And before I wrap up my prepared remarks, I would like to briefly highlight our progress on sustainability. During fiscal 2025, we achieved an estimated 40% reduction in scope 1 and 2 emissions, driven by our transition to 100% renewable electricity at our largest site located in Minneapolis. I encourage everyone to review the report in the corporate and social responsibility section of our website. I'm proud of the …
🍪 쿠키
당사는 이 사이트 운영 및 분석을 위해 쿠키를 사용합니다. 거부해도 콘텐츠 접근에는 영향을 미치지 않습니다.